SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, a SRC family tyrosine kinase inhibitor (Dasatinib) was already approved for treatment of chronic myeloid leukemia stressing the need of further studies on prevalence of activating SRC mutations in iCCA [41].